Valuation: GALA BIOP

Market Cap 2.42B 2.13B 2.01B 1.83B 3.42B 232B 3.45B 24.07B 9.33B 118B 9.08B 8.89B 385B P/E 2026 *
-58.4x
P/E 2027 * -126x
Enterprise Value 2.42B 2.13B 2.01B 1.83B 3.42B 232B 3.45B 24.07B 9.33B 118B 9.08B 8.89B 385B EV / Sales 2026 *
-
EV / Sales 2027 * 45.6x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 29/12/2017
Director of Finance/CFO 41 30/12/2017
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 29/12/2017
Chairman 66 01/06/2024
Director/Board Member 69 29/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.51%-2.71%+40.55%+77.66% 59.35B
+2.12%+5.26%+32.50%+21.28% 27.16B
+2.71%-1.96%-13.79%+364.46% 26.54B
+0.81%+0.61%-0.49%-5.14% 24.93B
+0.75%+1.15%+23.40%-9.32% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.17%-8.07%+499.10% 14.2B
+2.15%-0.92%+48.93%+169.79% 14.36B
Average +0.60%-0.12%+36.06%+171.96% 30.46B
Weighted average by Cap. +0.11%-0.24%+36.91%+132.99%

Financials

2026 *2027 *
Net sales - 53.09M 46.7M 44.03M 40.17M 75.12M 5.1B 75.7M 528M 205M 2.59B 199M 195M 8.44B
Net income -38.3M -33.69M -31.75M -28.97M -54.18M -3.68B -54.6M -381M -148M -1.87B -144M -141M -6.09B -21.38M -18.8M -17.73M -16.17M -30.24M -2.05B -30.48M -213M -82.43M -1.04B -80.26M -78.52M -3.4B
Net Debt - -
Logo GALA BIOP
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-